What medications are available for treating autoimmune diseases and what are their mechanisms of action?

Medications for Treating Autoimmune Diseases

A comprehensive armamentarium of immunosuppressive and immunomodulatory drugs is available for treating autoimmune diseases, organized into conventional synthetic DMARDs, biologic agents, targeted synthetic small molecules, and corticosteroids, each with distinct mechanisms targeting different components of the immune cascade.

Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs)

Azathioprine

• Mechanism: Purine analog that inhibits DNA synthesis, affecting rapidly dividing B and T cells by interfering with nucleotide production 1, 2
• Dosing: 1-2 mg/kg/day (typically starting at 50 mg daily) 3
• Key consideration: Check thiopurine methyltransferase (TPMT) activity before initiation to assess myelosuppression risk 2

Mycophenolate Mofetil (MMF)

• Mechanism: Next-generation purine antagonist with dual anti-proliferative and anti-inflammatory actions. Reduces purine-based nucleotide synthesis necessary for DNA creation, decreases lymphocyte proliferation, reduces adhesion molecule production, increases T-lymphocyte apoptosis, and diminishes inducible nitric oxide synthase (iNOS) and oxidative stress 1
• Dosing: 1,500-2,000 mg/day (start at 1,000 mg daily) 3
• Preferred use: Most effective for azathioprine intolerance (58% response) rather than refractory disease (23% response) 1
• Critical warning: Category D in pregnancy with severe cranial, facial, and cardiac abnormalities reported. Requires two methods of birth control during treatment and up to 12 weeks after withdrawal 3

Methotrexate

• Mechanism: Folic acid antagonist that interferes with purine and pyrimidine synthesis, impairing nucleotide production 2
• Note: Conditionally recommended AGAINST as first-line for rapidly progressive interstitial lung disease in systemic autoimmune rheumatic diseases 4

Leflunomide

• Status: Conditionally recommended AGAINST for rapidly progressive ILD in SARD 4

Calcineurin Inhibitors (CNI)

Cyclosporine and Tacrolimus

• Mechanism: Inhibit phosphatase activity of calcineurin, impairing activation and translocation of nuclear factors critical for IL-2 transcription. IL-2 deficiency inhibits cell cycles necessary for lymphocyte proliferation and cell-mediated immune responses 1
• Efficacy: Cyclosporine effective in 93% of autoimmune hepatitis cases; tacrolimus achieved improvement in 98% as salvage therapy 1
• Dosing:
  • Cyclosporine: 2-5 mg/kg daily, target trough 100-300 ng/mL
  • Tacrolimus: 0.075 mg/kg daily (0.5-1 mg daily), maintenance 1-3 mg twice daily, target trough 0.6-1.0 ng/mL 1
• Cautions: Neurotoxicity, expensive, paradoxical autoimmune effects possible, unable to consistently prevent recurrent autoimmune hepatitis post-transplant 1

Biologic Agents

TNF Inhibitors (TNFi)

Five distinct agents with varying structures 5:

• Infliximab: Chimeric mouse-human monoclonal antibody with murine variable region and human IgG1 constant region
• Adalimumab & Golimumab: Fully humanized anti-TNFα monoclonal antibodies
• Etanercept: Fusion protein of two extracellular portions of human TNF receptor 2 (p75) and Fc portion of human IgG1
• Certolizumab pegol: Fab' fragment lacking Fc portion, covalently linked to polyethylene glycol chains

Mechanism: Block tumor necrosis factor-alpha, a key proinflammatory cytokine 5

Approved indications: Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondyloarthritis, psoriasis, Crohn's disease, ulcerative colitis, Behçet's disease 5

Important distinction: Infliximab, adalimumab, and golimumab induce clinical/endoscopic remission in IBD; etanercept does NOT 5

Rituximab

• Mechanism: Anti-CD20 monoclonal antibody causing B-cell depletion 4, 6
• Applications: Conditionally recommended as first-line for rapidly progressive ILD in SARD 4; approved for rheumatoid arthritis, showing promise in SLE, Sjögren's syndrome, vasculitides, autoimmune cytopenias, neurologic and dermatologic autoimmune diseases 6

IL-6 Receptor Antagonists

Tocilizumab and Sarilumab 5:

• Mechanism: Block interleukin-6 receptor signaling
• Efficacy: Rapid and sustained improvement in clinical/radiographic outcomes in RA, low immunogenicity risk
• Flexibility: Available as IV and subcutaneous formulations
• Note: Conditionally recommended AGAINST as first-line for RP-ILD in SARD 4

Abatacept

• Mechanism: Recombinant fusion protein that selectively modulates co-stimulatory signals necessary for T-cell activation 5
• Approved: Rheumatoid arthritis (with/without MTX), psoriatic arthritis
• Note: Conditionally recommended AGAINST as first-line for RP-ILD 4

IL-17 and IL-23 Inhibitors

• Mechanism: Block IL-17 or IL-23 cytokine pathways 5
• Primary use: Axial spondyloarthritis, psoriatic arthritis, psoriasis

Targeted Synthetic Small Molecules

JAK Inhibitors (JAKi)

Tofacitinib, Baricitinib, and others 5, 7:

• Mechanism: Inhibit Janus kinase family enzymes responsible for signal transduction from multiple cytokine receptors, blocking intracellular signaling pathways
• Approved indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, alopecia areata 7
• Advantage: Oral administration, broad immunomodulatory effects
• Safety considerations: Recent warnings regarding cardiovascular events and malignancies compared to TNFi; requires careful patient selection 7

Corticosteroids

Prednisone/Prednisolone

• Mechanism: Broad anti-inflammatory and immunosuppressive effects through multiple pathways
• Dosing in autoimmune hepatitis: Start 0.5 mg/kg/day (up to 1 mg/kg/day in severe cases), taper according to biochemical response 3
• Critical warning: STRONGLY recommended AGAINST as first-line for systemic sclerosis-ILD due to scleroderma renal crisis risk, particularly at doses >15 mg daily 4
• Long-term monitoring: Adequate calcium intake and vitamin D supplementation essential 3

Budesonide

• Mechanism: Next-generation corticosteroid with 90% first-pass hepatic clearance and rapid degradation to less active metabolites 1
• Efficacy: In autoimmune hepatitis, budesonide 3 mg three times daily plus azathioprine normalized aminotransferases more frequently (47% vs 18%) with fewer side effects (28% vs 53%) than prednisone-based regimens at 6 months 1
• Limitation: Durability of response and histological resolution rates unknown 1

Additional Therapies

Intravenous Immunoglobulin (IVIG)

• Mechanism: Multiple immunomodulatory effects
• Use: Conditionally recommended as first-line option for RP-ILD in SARD 4

Cyclophosphamide

• Mechanism: Alkylating agent with potent immunosuppressive effects
• Use: Conditionally recommended for RP-ILD in SARD, typically not used in combination with other therapies 4

Nintedanib and Pirfenidone

• Mechanism: Antifibrotic agents
• Status: Conditionally recommended AGAINST as first-line for RP-ILD in SARD 4

Treatment Hierarchy for Specific Conditions

For systemic autoimmune rheumatic disease-associated ILD 4:

1. Preferred first-line: Mycophenolate (ranked highest across all SARD-ILD types)
2. Additional first-line options: Rituximab, azathioprine, tocilizumab, cyclophosphamide, JAK inhibitors (disease-dependent)
3. Progression management: Switch to alternative first-line agent or add nintedanib, CNI, pirfenidone depending on clinical situation

Critical pitfall: Avoid long-term glucocorticoids in systemic sclerosis-ILD due to renal crisis risk 4. Short-term use (≤3 months) may be considered in other SARD-ILD with careful monitoring.

The selection among these agents depends on the specific autoimmune disease, disease severity, prior treatment failures, comorbidities, pregnancy potential, and cost considerations. Mycophenolate emerges as the preferred immunosuppressant across multiple autoimmune conditions in recent guidelines 4, 3, while biologic agents and JAK inhibitors provide targeted options when conventional therapy fails or is contraindicated.